Azar Alex M II sold $145K of GH
Azar Alex M II sold 826 shares of Guardant Health, Inc. (GH) at $175.00 ($0.14M total) on 2026-09-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The filing provides the first public notice of the director's sale, offering transparency but limited trading relevance due to the small amount.
Market read
A routine insider sale with minimal market impact; primarily of interest to compliance and monitoring teams.
What to watch
Potential upcoming clinical trial results or FDA interactions that are not disclosed in the filing.
Background
SEC Form 4 filings disclose insider transactions. Directors often use pre‑arranged 10b5‑1 plans to sell shares in a structured manner.
Ticker impact
Director Azar Alex M II sold 826 shares of Guardant Health for $144,550 via a 10b5-1 plan on 2026-09-16.
Minimal short-term price pressure, unlikely to move the stock materially.
The sale size ($145k) is small relative to market cap; directors often use 10b5-1 plans, so market reaction is typically muted.
Market effects
Slight reminder of insider activity in the liquid‑biopsy sector, but no broader sector impact.
None; the filing is U.S.‑focused and affects only Guardant Health.
Low; limited to investors tracking insider transactions.
Counterpoint
If the director is reducing exposure, it could signal concerns about upcoming data or regulatory outcomes.
Key entities
- CompanyGuardant Health, Inc.
NASDAQ‑listed provider of liquid biopsy tests (ticker GH).
- IndividualAzar Alex M II
Director of Guardant Health who executed the sale.
